Hemostatic alterations accompanying sickle cell pain crises
- PMID:956696
Hemostatic alterations accompanying sickle cell pain crises
Abstract
Three patients with sickle-cell disease (SSD) were followed, weekly, for 1 1/2 to 2 years, during which time they experienced one or more episodes of crisis. Crisis was associated with reproducible sequential hemostatic alterations indicating intravascular fibrin formation and a marked disturbance in platelet economy. With crisis onset, or possibly before, there was an increase in plasma high-molecular-weight fibrinogen complexes and a transient fall in platelet count, with a subsequent rise in both fibrinogen concentration and platelet count; plasma fibrinogen peaked 1 week after crisis onset and platelet count approximately 2 weeks after onset. Subsidence of crisis was associated with a fall in high-molecular-weight fibrinogen complexes and a subsequent increase in fibrinogen first derivative, an early fibrinogen breakdown product. Hemostatic findings and patient clinical status were generally correlated, the findings during asymptomatic periods being essentially normal. Agents affecting platelet function (aspirin alone or in combination with dipyridamole) appeared to reduce the extent of laboratory abnormality, suggesting potential clinical usefulness in this disorder.
Similar articles
- Coagulation factor XIII concentration in sickle-cell disease.Ittyerah R, Alkjaersig N, Fletcher A, Chaplin H.Ittyerah R, et al.J Lab Clin Med. 1976 Oct;88(4):546-54.J Lab Clin Med. 1976.PMID:965808
- Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises.Chaplin H Jr, Alkjaersig N, Fletcher AP, Michael JM, Joist JH.Chaplin H Jr, et al.Thromb Haemost. 1980 Jul 15;43(3):218-21.Thromb Haemost. 1980.PMID:7006142Clinical Trial.No abstract available.
- Using serial haemorheological parameters to assess clinical status in sickle cell anaemia patients in vaso-occlussive crisis.Awodu OA, Famodu AA, Ajayi OI, Enosolease ME, Olufemi OY, Olayemi E.Awodu OA, et al.Clin Hemorheol Microcirc. 2009;41(2):143-8. doi: 10.3233/CH-2009-1167.Clin Hemorheol Microcirc. 2009.PMID:19252237
- [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].Koga S.Koga S.Rinsho Byori. 2004 Apr;52(4):355-61.Rinsho Byori. 2004.PMID:15164605Review.Japanese.
- Newer techniques in the study of hemostatic disorders.Pepper DS, Preston FE, Mibashan RS.Pepper DS, et al.Semin Hematol. 1978 Jan;15(1):73-92.Semin Hematol. 1978.PMID:341329Review.No abstract available.
Cited by
- The Platelet Count and its Implications in Sickle Cell Disease Patients Admitted for Intensive Care.Shome DK, Jaradat A, Mahozi AI, Sinan AS, Ebrahim A, Alrahim M, Ebraheem MS, Mansoor EJ, Majed KS, Azeez Pasha SA.Shome DK, et al.Indian J Crit Care Med. 2018 Aug;22(8):585-590. doi: 10.4103/ijccm.IJCCM_49_18.Indian J Crit Care Med. 2018.PMID:30186009Free PMC article.
- Advances in new drug therapies for the management of sickle cell disease.Ataga KI, Desai PC.Ataga KI, et al.Expert Opin Orphan Drugs. 2018;6(5):329-343. doi: 10.1080/21678707.2018.1471983. Epub 2018 May 14.Expert Opin Orphan Drugs. 2018.PMID:30873300Free PMC article.
- Myocardial infarction in sickle cell disease.Martin CR, Johnson CS, Cobb C, Tatter D, Haywood LJ.Martin CR, et al.J Natl Med Assoc. 1996 Jul;88(7):428-32.J Natl Med Assoc. 1996.PMID:8764524Free PMC article.
- Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism.Kenny MW, George AJ, Stuart J.Kenny MW, et al.J Clin Pathol. 1980 Jul;33(7):622-5. doi: 10.1136/jcp.33.7.622.J Clin Pathol. 1980.PMID:7430367Free PMC article.
- Studies of the kallikrein-kinin system in patients with sickle cell anemia.Miller RL, Verma PS, Adams RG.Miller RL, et al.J Natl Med Assoc. 1983 Jun;75(6):551-6.J Natl Med Assoc. 1983.PMID:6603519Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Other Literature Sources